Company intelligence / Profile preview

North American Vaccine

Beltsville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

North American Vaccine was a biopharmaceutical company focused on the development and commercialization of vaccines for the prevention of infectious diseases in children and adults. The company's portfolio included Certiva, a component pertussis vaccine combined with diphtheria and tetanus toxoids, and NeisVac-C, a conjugate vaccine for Meningococcal C. Following its acquisition by Baxter International in 2000, its operations were integrated into Baxter's BioScience division. The company was notable for its research into Group B Streptococcus and conjugate vaccine technologies.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Partnerships

Baxter InternationalNational Institutes of Health

Beyond the preview

Go deeper on North American Vaccine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on North American Vaccine.

Explore the full profile